Roche scores a no­table PhI­II suc­cess with Tecen­triq com­bo in blad­der can­cer, but is this an­oth­er case of too lit­tle too late?

Two years af­ter Roche’s PD-L1 drug Tecen­triq failed a key test for front­line blad­der can­cer as a monother­a­py, in­ves­ti­ga­tors are back with Phase III …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.